Semaglutide Linked to Reduced Risk for Alzheimer Diagnosis in T2DM
By Elana Gotkine HealthDay Reporter
FRIDAY, Nov. 1, 2024 -- For patients with type 2 diabetes mellitus, semaglutide is associated with a reduced risk for a first-time Alzheimer disease (AD) diagnosis compared with other antidiabetic medications, according to a study published online Oct. 24 in Alzheimer's & Dementia.
William Wang, from the Case Western Reserve University School of Medicine in Cleveland, and colleagues conducted emulation target trials based on a nationwide database of electronic health records for 116 million U.S. patients. Semaglutide was compared to seven other antidiabetic medications in seven target trials emulated among 1,094,761 eligible patients with type 2 diabetes without a prior AD diagnosis. A first-ever diagnosis of AD within a three-year follow-up period was examined.
The researchers found a significant reduction in the risk for a first-time AD diagnosis in association with semaglutide, with the strongest reduction compared with insulin and the weakest compared with other glucagon-like peptide receptor agonists (hazard ratios, 0.33 and 0.59, respectively). Across obesity status, gender, and age groups, similar results were seen.
"Additional preclinical and clinical studies are needed to shed light on the mechanisms of the potential benefits of semaglutide in preventing or delaying the onset of AD and establish causal effects through randomized trials," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Shorter Leukocyte Telomere Length Linked to Higher Incidence of Age-Related Brain Diseases
THURSDAY, June 12, 2025 -- Individuals with shorter leukocyte telomere length (LTL) have a higher incidence of stroke, dementia, and late-life depression (LLD), individually and...
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...
Epilepsy More Common With Frontotemporal Dementia
TUESDAY, June 10, 2025 -- Epilepsy is more common among those with frontotemporal dementia (FTD) than among people with Alzheimer disease (AD) or healthy controls, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.